These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19721253)

  • 1. Study on mechanism for amorphous drug stabilization using gelucire 50/13.
    Shimpi SL; Mahadik KR; Paradkar AR
    Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):937-42. PubMed ID: 19721253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stabilization and improved in vivo performance of amorphous etoricoxib using Gelucire 50/13.
    Shimpi SL; Chauhan B; Mahadik KR; Paradkar A
    Pharm Res; 2005 Oct; 22(10):1727-34. PubMed ID: 16180131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of polyglycolized glycerides in protection of amorphous form of etoricoxib during compression.
    Shimpi S; Mahadik K; Takada K; Paradkar A
    Chem Pharm Bull (Tokyo); 2007 Oct; 55(10):1448-51. PubMed ID: 17917287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
    Dhumal RS; Shimpi SL; Paradkar AR
    Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefuroxime axetil solid dispersion with polyglycolized glycerides for improved stability and bioavailability.
    Dhumal RS; Biradar SV; Aher S; Paradkar AR
    J Pharm Pharmacol; 2009 Jun; 61(6):743-51. PubMed ID: 19505364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation, characterization, and in vivo evaluation of celecoxib-PVP solid dispersion nanoparticles using supercritical antisolvent process.
    Ha ES; Choo GH; Baek IH; Kim MS
    Molecules; 2014 Dec; 19(12):20325-39. PubMed ID: 25486246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of atypical dissolution behavior of an encapsulated amorphous solid dispersion.
    Puri V; Dantuluri AK; Bansal AK
    J Pharm Sci; 2011 Jun; 100(6):2460-8. PubMed ID: 21246560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anomalous dissolution behavior of celecoxib in PVP/Isomalt solid dispersions prepared using spray drier.
    Ghanavati R; Taheri A; Homayouni A
    Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():501-511. PubMed ID: 28024614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of PVP K30 and/or L-arginine on stability constant of etoricoxib-HPbetaCD inclusion complex: preparation and characterization of etoricoxib-HPbetaCD binary system.
    Shah M; Karekar P; Sancheti P; Vyas V; Pore Y
    Drug Dev Ind Pharm; 2009 Jan; 35(1):118-29. PubMed ID: 18979307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spray drying for generation of a ternary amorphous system of celecoxib, PVP, and meglumine.
    Gupta P; Bansal AK
    Pharm Dev Technol; 2005; 10(2):273-81. PubMed ID: 15926676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles.
    Liu Y; Sun C; Hao Y; Jiang T; Zheng L; Wang S
    J Pharm Pharm Sci; 2010; 13(4):589-606. PubMed ID: 21486533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability study of amorphous valdecoxib.
    Ambike AA; Mahadik KR; Paradkar A
    Int J Pharm; 2004 Sep; 282(1-2):151-62. PubMed ID: 15336390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
    Caron V; Tajber L; Corrigan OI; Healy AM
    Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barrier coated drug layered particles for enhanced performance of amorphous solid dispersion dosage form.
    Puri V; Dantuluri AK; Bansal AK
    J Pharm Sci; 2012 Jan; 101(1):342-53. PubMed ID: 21935949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling of drug release from celecoxib-PVP-meglumine amorphous systems.
    Gupta P; Bansal AK
    PDA J Pharm Sci Technol; 2005; 59(6):346-54. PubMed ID: 16471422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Factors Governing the Liquid and Glassy States Recrystallization of Celecoxib in Binary Mixtures with Excipients of Different Molecular Weights.
    Grzybowska K; Chmiel K; Knapik-Kowalczuk J; Grzybowski A; Jurkiewicz K; Paluch M
    Mol Pharm; 2017 Apr; 14(4):1154-1168. PubMed ID: 28241116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solubility advantage from amorphous etoricoxib solid dispersions.
    Dani P; Puri V; Bansal AK
    Drug Dev Ind Pharm; 2014 Jan; 40(1):92-101. PubMed ID: 23301771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing various techniques to produce micro/nanoparticles for enhancing the dissolution of celecoxib containing PVP.
    Homayouni A; Sadeghi F; Varshosaz J; Garekani HA; Nokhodchi A
    Eur J Pharm Biopharm; 2014 Sep; 88(1):261-74. PubMed ID: 24952357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective.
    Gupta P; Kakumanu VK; Bansal AK
    Pharm Res; 2004 Oct; 21(10):1762-9. PubMed ID: 15553220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular interactions in celecoxib-PVP-meglumine amorphous system.
    Gupta P; Bansal AK
    J Pharm Pharmacol; 2005 Mar; 57(3):303-10. PubMed ID: 15807985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.